New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ABBV;DELL;FII;ESI;NCIT;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
January 29, 2015
09:13 EDTABTAbbott sees 6% negative impact to FY sales from forex
Subscribe for More Information
07:50 EDTABTAbbott sees Q1 EPS excl items 41c-43c, consensus 41c
07:50 EDTABTAbbott sees FY15 EPS excl items $2.10-$2.20, consensus $2.14
Subscribe for More Information
07:50 EDTABTAbbott reports Q4 Nutrition sales up 8.9% to $1.8B
Reports Q4 Diagnostics sales up 8.6% to $1.23B; Reports Q4 Established Pharmaceuticals sales up 35.4% to 922M; Reports Q4 Medical Devices sales up 0.4% to $1.38B.
07:48 EDTABTAbbott expects top tier earnings growth in 2015 despite currency headwinds
Subscribe for More Information
07:47 EDTABTAbbott reports Q4 EPS excl items 71c, consensus 67c
Subscribe for More Information
January 28, 2015
15:38 EDTABTNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Celgene (CELG), consensus 99c... ConocoPhillips (COP), consensus 59c... Abbott Laboratories (ABT), consensus 67c... Occidental Petroleum (OXY), consensus 68c... Colgate-Palmolive (CL), consensus 74c... Ford (F), consensus 23c... Dow Chemical (DOW), consensus 69c... Alibaba (BABA), consensus 75c... Thermo Fisher (TMO), consensus $1.94; Time Warner Cable (TWC), consensus $2.09... Phillips 66 (PSX), consensus $1.34... Alexion Pharmaceuticals (ALXN), consensus $1.29... Baxter International (BAX), consensus $1.31... Cardinal Health (CAH), consensus $1.10... Raytheon (RTN), consensus $1.08... Northrop Grumman (NOC), consensus $2.25... Viacom (VIAB), consensus $1.28... Valero Energy (VLO), consensus $1.32... Sherwin-Williams (SHW), consensus $1.38... Hershey (HSY), consensus $1.06... Mead Johnson (MJN), consensus 88c... Zimmer (ZMH), consensus $1.71... Xcel Energy (XEL), consensus 34c... Royal Caribbean (RCL), consensus 42c... Coach (COH), consensus 66c... Kate Spade (KATE), consensus 24c... Harley-Davidson (HOG), consensus 34c... Stanley Black & Decker (SWK), consensus $1.52... L-3 Communications (LLL), consensus $2.27... JetBlue (JBLU), consensus 24c.
11:34 EDTABTEC clears Abbott sale of non-U.S. EPD-DM business to Mylan, with conditions
The European Commission has cleared under the EU Merger Regulation the proposed acquisition of Abbott Laboratories' (ABT) Non-U.S. Developed Markets Specialty and Branded Generics Business, or EPD-DM, by Mylan (MYL). The decision is conditional upon the divestment of a number of Mylan's businesses in Germany, the United Kingdom, France, Ireland and Italy. The Commission had concerns that the transaction, as initially notified, would have reduced competition on the market for several medicines. The commitments offered by Mylan address these concerns, the EC said.
09:59 EDTNCITOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:03 EDTNCITGovernment Services upgraded to Market Weight at Wells Fargo
Wells Fargo upgraded the Government Services sector to Market Weight from Underweight citing a stable outlook for Federal Funding and an improved pace of award activity. Along with the sector, Wells upgraded Booz Allen (BAH), CACI (CACI), Leidos (LDOS), ManTech (MANT) and NCI, Inc. (NCIT) to Market Perform from Underperform. The firm keeps Market Perform ratings on ICF International (ICFI) and SAIC (SAIC).
06:59 EDTNCITNCI, Inc. upgraded to Market Perform from Underperform at Wells Fargo
Subscribe for More Information
January 22, 2015
16:03 EDTFIIFederated Investors reports Q EPS 38c, consensus 38c
Reports Q4 revenue $217.85M, consensus $221.28M.
January 16, 2015
10:10 EDTABBVAbbVie announces FDA approval of DUOPA enteral suspension
Subscribe for More Information
07:04 EDTABBVEnanta says EU grants marketing authorizations for AbbVie's Viekirax
Subscribe for More Information
05:05 EDTABBVAbbVie granted marketing authorization by EC for VIEKIRAX + EXVIERA
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX + EXVIERA. The treatment has been approved with or without ribavirin for patients with genotype 1 chronic hepatitis C virus infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 chronic hepatitis C patients.
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use